MOMA Therapeutics, from the United States, collaborates with Roche, based in Switzerland, to identify and prosecute precision oncology targets. MOMA is set to receive $66 million upfront and more than $2 billion in milestone payments and royalties.
November 2024:
Flare Therapeutics, based in the United States, is collaborating with Roche, based in Switzerland, to discover cancer drug targets. Flare will receive $70 million upfront and more than $1.8 billion in milestone payments.
Roche, based in Switzerland, is acquiring Poseida Therapeutics, based in the United States, for a total equity value of up to $1.5 billion. Poseida’s lead asset is a CAR-T candidate for multiple myeloma.
August 2024:
Merck, based in the United States, is set to acquire a clinical candidate from Curon Biopharmaceutical, which is based in China. The asset being acquired is a clinical-stage T-cell-engager bispecific antibody for non-Hodgkin’s lymphoma and acute lymphocytic leukemia. Curon is poised to receive $700 million upfront and could earn up to $600 million in milestone payments.
There is money out there... The August one is interesting, circa $2B AUD Deal
If ours is as good or better?
IMU Price at posting:
3.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)